Axsome Therapeutics, Inc. (AXSM) Cash Flow Statement

The persistent divergence between net income and operating cash flow suggests that the company's path to self-sustainability remains obstructed by high cash-based operating expenses. Investors should monitor whether the narrowing of this gap in certain quarters represents a structural improvement in cash conversion or merely temporary fluctuations in working capital timing.

The erratic nature of FCF, which briefly touched positive territory in 2025Q3, suggests that the company is still in a high-burn phase where commercial success is frequently offset by the heavy fixed costs of its specialized sales force. This trajectory implies that the company remains highly sensitive to the timing of revenue recognition versus the rigid, recurring nature of its SG&A expenditures.

The significant swings in working capital suggest that the company's cash position is highly susceptible to the timing of payments and receivables, which can create misleading snapshots of operational health. Analysts should look past these quarterly shifts to determine if the core business is generating sufficient cash to cover its operational overhead without relying on favorable timing of payables.